

PRESS RELEASE

Cordlife signs strategic alliance agreement with Cordlabs Asia and China Cord Blood Corporation to expand umbilical cord tissue storage services

- **Strengthens partnership with Cordlabs Asia, a leading stem cell research and development company and China Cord Blood Corporation (CCBC), the largest cord blood banking operator in China**
- **Capitalise on economies of scale by expanding its geographical reach through collaborative partnerships**

SINGAPORE, 3 March 2014 - Cordlife Group Limited ("Cordlife", and together with its subsidiaries, the "Group"), a multi-product healthcare company catering to the mother and child segment, announced today that it has extended its strategic alliance and co-operation with CordLabs Asia Pte. Ltd. ("CAP") in relation to the provision of human postnatal umbilical cord tissue storage services (the "Services") to certain territories in the People's Republic of China (the "PRC").

CAP is a wholly-owned subsidiary of CellResearch Corporation Pte. Ltd. ("CellResearch") and has been authorised by CellResearch to use and exploit stem or progenitor cells derived from human postnatal umbilical cord tissue for storage purposes only ("CRC Technology"). This CRC technology is pioneered and patented by CellResearch. CellResearch is a leading stem cell research and development company founded in 2002, which provides high quality primary cell strains, culture media and research service support to researchers and corporations the world over.

Pursuant to the strategic alliance, Cordlife will work with CAP and China Cord Blood Corporation ("CCBC") in relation to the provision of the Services on an exclusive basis.

CCBC, listed on the New York Stock Exchange, is the largest cord blood banking operator in the PRC. On November 12, 2012, Cordlife completed the acquisition of 10% of issued shares in CCBC.

Mr Jeremy Yee, Executive Director and Group CEO of Cordlife said, "We view the strategic alliance as highly complementary to our respective strengths; Cordlife's expertise in tissue banking and storage and experience in Asian markets outside PRC; CAP's research & development capabilities; and CCBC's local knowledge and distribution networks. Both CAP and CCBC form a good fit with Cordlife, as we all share the same vision of bettering the lives of people and maintaining the highest quality standards. With

The initial public offering of Cordlife's shares was sponsored by PrimePartners Corporate Finance Pte. Ltd., who assumes no responsibility for the contents of this release.

the strategic alliance, Cordlife will be able to capitalise on the growth opportunities outside of our existing markets.

Initially, our umbilical cord tissue banking services have been met with good market acceptance and we are excited that umbilical cord tissue storage services will be offered to even more prospective clients in the future with the strategic alliance signed.”

Mr. Gavin Tan, Co-Founder of CAP, said: “As a stem cell research and development company founded in 2002, which provides high quality primary cell strains, culture media and research service support to researchers and corporations globally, we are pleased to partner with Cordlife. All of us place a strong emphasis on high standards and quality assurance for consumers.”

This strategic alliance shall be for an initial period of three (3) years and may be extended for such period as agreed between the relevant parties. Cordlife was also granted a right of first refusal should CAP wish to enter into any similar arrangement with any third party in the PRC.

Mr Yee continued: “The strategic alliance allow us to expand our geographical coverage in Asia through the bundling of both parties’ services. Essentially, this strategic alliance allows us to expand our geographical footprint (economies of scale), as well as increase the scope of products and services that we will be providing (economies of scope). Overall, we remain focused on our key strategy to grow via economies of scale and scope through collaborative networks and strategic alliances.”

The strategic alliance is not expected to have a material impact on Cordlife’s financial performance for the financial year ending 30 June 2014.

- The End -

ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), is a multi-product healthcare company catering to the mother and child segment and a leading cord blood and tissue banking services provider. Amongst the first private cord blood banks in Asia, Cordlife has established a dominant market leader position in Singapore¹. Today, it has the larger market share of the only two private cord blood banks in Singapore. In Hong Kong, it is amongst the three market leaders for private cord blood banks. Cordlife completed the acquisition of the cord blood and cord tissue banking businesses and assets in India, the Philippines and Indonesia from Australia-listed Life Corporation Limited (formerly known as Cordlife Limited) in June 2013.

Cordlife, through its collaborative relationships or arrangements with major private hospitals and clinics such as Thomson Medical and Parkway East Hospital, has continued to increase public awareness of its cord blood banking services in Singapore. Overseas, the Group has a 10% direct stake in China Cord Blood Corporation – a top cord blood bank operator in China holding majority shares in the Beijing, Guangdong and Zhejiang Cord Blood Banks, and an approximately 24% share in Shandong Cord Blood Bank. In October 2013, Cordlife also acquired a 19.92% stake, which was subsequently increased to approximately 31.81% in December 2013, in StemLife Berhad. StemLife Berhad is a fully licensed cord blood banking facility with the Ministry of Health Malaysia currently listed on the ACE Market of Bursa Malaysia.

Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy.

Cordlife’s track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2012 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7; Baby & Kid Brands Awards year 2013, “My Favourite Cord Blood Bank” by Hong Kong Economic Times; and Baby Kingdom Top 10 Family Brand Award 2012². In October 2012, Cordlife was awarded the prestigious SIAS Investors’ Choice Awards as runner-up in the “Most Transparent Company Award 2012” New Issues Category. In August 2013, we were presented with Merit Award for the Singapore Corporate Awards 2013, “Best Investor Relations Award”. In November 2013, Cordlife was named the “Most Transparent Company 2013” in the Retail & Household Goods Category and Mainboard Small Caps Category at the 14th SIAS Investors’ Choice Awards.

¹ Source : Deloitte & Touche Financial Advisory Services Limited report, 10 April 2013

² Awarded to Cordlife (Hong Kong) Limited

ISSUED ON BEHALF OF : Cordlife Group Limited
BY : Financial PR Pte Ltd
4 Robinson Road #04-01
The House of Eden
Singapore 048543

CONTACT : Mr Gabriel Tan / Mr Kamal Samuel
OFFICE : 6438-2990
EMAIL : gabriel@financialpr.com.sg /
kamal@financialpr.com.sg
